Sverige -
svenska -
Läkemedelsverket (Medical Products Agency)
cisatracurium mylan 2 mg/ml injektions-/infusionsvätska, lösning
mylan hospital as - cisatrakuriumbesilat - injektions-/infusionsvätska, lösning - 2 mg/ml - cisatrakuriumbesilat 2,68 mg aktiv substans - cisatrakurium
Sverige -
svenska -
Läkemedelsverket (Medical Products Agency)
cisatracurium mylan 5 mg/ml injektions-/infusionsvätska, lösning
mylan hospital as - cisatrakuriumbesilat - injektions-/infusionsvätska, lösning - 5 mg/ml - cisatrakuriumbesilat 6,7 mg aktiv substans - cisatrakurium
Europeiska unionen -
svenska -
EMA (European Medicines Agency)
nevanac
novartis europharm limited - nepafenak - pain, postoperative; ophthalmologic surgical procedures - ögonsjukdomar - nevanac is indicated for: , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.